An assessment of COVID-19 treatments, including remdesivir and dexamethasone 

On May 1st, ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an estimate based on peer-reviewed methods of calculating the minimum costs of production for a course of therapy; and 2) traditional cost-effectiveness analyses looking at the incremental health benefits and costs within the health system. The models will be used to track and evaluate any potential future treatments for COVID-19. Click here to learn more about ICER’s adapted methods for assessing pricing during a pandemic.

Details on subsequent updates to the ICER-COVID models will be listed here.

For questions, please contact Meaghan Cummings at mcummings@icer-review.org .